Recently, the anti-HER2 antibody–drug conjugate demonstrated high anti-tumor activity and was well-tolerated in MMTV-HER2 models but caused several persistent toxicities in patients with HER2+-metastatic BC, resulting in the early termination of the phase I clinical trial [121]. This evidence concerns the gene ERBB2 and breast cancer.